Menu
Back to User profile » Dr Benedetto Maurizio Celesia
Papers published by Dr Benedetto Maurizio Celesia:
The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
Squillace N, Ricci E, Menzaghi B, De Socio GV, Passerini S, Martinelli C, Mameli MS, Maggi P, Falasca K, Cordier L, Celesia BM, Salomoni E, Di Biagio A, Pellicanò GF, Bonfanti P
Drug Design, Development and Therapy 2020, 14:5515-5520
Published Date: 15 December 2020
Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort
Bonfanti P, De Vito A, Ricci E, Menzaghi B, Orofino G, Squillace N, Molteni C, De Socio GV, Salomoni E, Celesia BM, Dentone C, Colombo V, Madeddu G
Infection and Drug Resistance 2020, 13:2291-2300
Published Date: 14 July 2020
Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project
Bagella P, Squillace N, Ricci E, Gulminetti R, De Socio GV, Taramasso L, Pellicanò G, Menzaghi B, Celesia BM, Dentone C, Orofino G, Bonfanti P, Madeddu G
Infection and Drug Resistance 2019, 12:1385-1391
Published Date: 23 May 2019
Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project
Bagella P, De Socio GVL, Ricci E, Menzaghi B, Martinelli C, Squillace N, Maggi P, Orofino G, Calza L, Carenzi L, Celesia BM, Penco G, Di Biagio A, Valsecchi L, Vichi F, Colombo V, Parruti G, Dentone C, Falasca K, Bonfanti P, Madeddu G
Infection and Drug Resistance 2018, 11:615-623
Published Date: 26 April 2018
Cost of HAART in Italy: multicentric evaluation and determinants from a large HIV outpatient cohort
Tontodonati M, Cenderello G, Celesia BM, Trezzi M, Ursini T, Costantini A, Marra D, Polilli E, Catalani C, Butini L, Sozio F, Mazzotta E, Sciacca A, Rizzardini G, Manzoli L, Cozzi-Lepri A, Parruti G
ClinicoEconomics and Outcomes Research 2015, 7:27-35
Published Date: 22 December 2014